Enlivex Ltd. Ordinary Shares
ENLVEnlivex Therapeutics Ltd. is a clinical-stage biotech company specializing in the development of immune rebalancing immunotherapies for the treatment of severe inflammatory and immune-related conditions. Their flagship product pipeline focuses on harnessing the body's immune system to improve outcomes in conditions such as sepsis, graft-versus-host disease, and other immune dysregulation disorders.
Company News
RAIN, an Arbitrum-based prediction market protocol, announced $200 million in ecosystem commitments through a partnership with Enlivex and $100 million in liquidity expansion ($50M USDT, $50M RAIN). The protocol is preparing for Version 2 launch featuring permissionless market creation, AMMs, on-chain order books, and AI-assisted market resolutio...
Enlivex Therapeutics reported positive Phase I/II trial results for Allocetra, showing significant pain reduction and functional improvement in knee osteoarthritis patients, with a favorable safety profile.
Enlivex Therapeutics received a notice of allowance for a Japanese patent application covering the use of its Allocetra™ product in treating osteoarthritis, a common and debilitating condition with limited treatment options.
Key Highlights
Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 or...
